NCT04679350终止2 期
A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous(IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 3
- 主要终点
- Changes from baseline in the clinical improvement score on an 8-point scale at Day 21
研究概览
简要总结
To explore the efficacy and confirm the safety of the concomitant administration of the standard of care and hzVSF-v13 in patients with COVID-19 infection
详细描述
A Multi center, Randomized, Double-blind, Parallel design
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults aged at least 19 years at screening
- •Those who have been admitted or scheduled to be admitted due to a diagnosis with COVID-19 by RT-PCR test within 4 days prior to screening
- •Patients whose findings of COVID-19 pneumonia have been confirmed by radiographic tests (CT and X-ray) at screening (e.g., ground glass opacity (GGO), crazy-paving pattern, or consolidation)
- •Those who fall under the following at screening:
- •Patients identified as moderate: Oxygen saturation in the atmosphere (SpO2) >93% (to be confirmed with respiratory rate ≥20/min or pulse rate ≥90 beats/min secondarily)
- •Patients identified as severe: Oxygen saturation in the atmosphere (SpO2) ≤93% or PaO2/FiO2 <300 (respiratory rate ≥30/min or pulse rate ≥125 beats/min secondarily)
- •Those who have voluntarily provided a written consent to participate in this clinical study
排除标准
- •Individuals with a clinically significant history of hypersensitivity reactions to the components of hzVSF-v13, drugs containing components of the same class, or other drugs (aspirin, non-steroidal anti-inflammatory drugs, antibiotics, etc.)
- •Individuals with a severe at screening
- •Breathing disorder that requires treatment of one or more of the following: Oxygen therapy using high-flow nasal cannula (HFNC), Noninvasive positive pressure ventilation (NIV), invasive mechanical ventilation, ECMO, Clinical diagnosis of respiratory failure
- •Shock (Systolic <90mmHg or diastolic <60mmHg, or in case need a blood pressure booster)
- •Multiple organ failure
- •Patients with pneumonia other than due to the novel coronavirus (SARS-CoV-2) infection (e.g., influenza virus pneumonia, bacterial pneumonia, and fungal pneumonia)
- •Patients with severe heart failure (NYHA Class III or higher)
- •Pregnant women
- •Men or women of childbearing potential who are planning to become pregnant or do not agree to use one or more of the clinically appropriate methods of contraception below from the first day until 120 days after the last day of investigational product administration
- •① Surgical infertility (e.g., bilateral tubal ligation, vasectomy)
- •② Hormonal contraceptives (Hormone releasing IUD, implantable form, patch, oral hormone)
- •③ Double-barrier method (concomitant use of two of the following: IUD, male or female condom, contraceptive diaphragm, contraceptive sponge, cervical cap, spermicide) Periodic abstinence (e.g., calendar, ovulation date, basal body temperature, post-ovulation methods) and coitus interruptus are not permitted as appropriate contraceptive methods, and effective contraceptive methods must be kept being used during the course of the clinical study.
- •Those who are scheduled to have organ transplantation
- •Those who have laboratory test results that fall under the following values at screening ① ALT or AST ≥5 times the upper limit of normal (ULN)
- •② eGFR < 30 mL/min/1.73m2
- •③ platelets < 50,000/mm3
- •Those who have a positive result for serology (hepatitis B, human immunodeficiency virus [HIV], and hepatitis C tests) at screening
- •Those who administered other investigational products within 30 days prior to the screening visit
- •Others who have been determined to be ineligible to participate in the clinical study according to the investigator's medical opinion
研究组 & 干预措施
Standard of care + 3 doses of hzVSF-v13 50 mg/dose IV
Experimental
Standard of care + 3 doses of hzVSF-v13 50 mg/dose IV
干预措施: hzVSF-v13 (Drug)
Standard of care + 3 doses of hzVSF-v13 200 mg/dose IV
Experimental
Standard of care + 3 doses of hzVSF-v13 200 mg/dose IV
干预措施: hzVSF-v13 (Drug)
Standard of care + 1 dose of hzVSF-v13 200 mg/dose IV + 2 doses of the placebo
Experimental
Standard of care + 1 dose of hzVSF-v13 200 mg/dose IV + 2 doses of the placebo
干预措施: hzVSF-v13 (Drug)
Standard of care + 3 doses of the placebo to match hzVSF-v13 (normal saline)
Placebo Comparator
Standard of care + 3 doses of the placebo to match hzVSF-v13 (normal saline)
干预措施: Placebo (Normal saline solution) (Drug)
结局指标
主要结局
Changes from baseline in the clinical improvement score on an 8-point scale at Day 21
时间窗: Day 21
Descriptive statistics for the changes from baseline in the clinical improvement score on an 8-point scale at Day 21 shall be presented for each treatment group, and a two-sample t-test or the Wilcoxon rank-sum test shall be performed depending on whether the normality assumption is satisfied in order to test differences of each study group compared to the control group.
次要结局
- Changes from baseline in the clinical improvement score on an 8-point scale at Day 7, Day 14, and Day 28(Day 7, Day 14, Day 28)
- Time to discontinuation of oxygen therapy after investigational product administration(Day 28)
- Time to recovery* after investigational product administration (days)(Day 28)
- Changes from baseline in PaO2/FiO2 at Day 7, Day 14, Day 21, and Day 28(Day 7, Day 14, Day 21, Day 28)
- Changes from baseline in the NEWS 2 score at Day 7, Day 14, Day 21, and Day 28(Day 7, Day 14, Day 21, Day 28)
- Mortality at Day 28 and Day 60 after investigational product administration(Day 28, Day 60)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 PneumoniaCOVID-19NCT04679415ImmuneMed, Inc.63
已完成
3 期
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus RaltegravirHIV InfectionNCT00708162Gilead Sciences724
已完成
2 期
PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructivePulmonary EmphysemaChronic BronchitisNCT00683722Mesoblast, Inc.62
已完成
2 期
Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential HypertensionEssential HypertensionHypertensionNCT06212648Shin Poong Pharmaceutical Co. Ltd.253
已完成
2 期
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative ColitisDigestive System DiseasesColitis, UlcerativeGastrointestinal DiseasesInflammatory Bowel DiseasesIntestinal DiseasesColonic DiseasesAutoimmune DiseaseAbdominal PainUlcerative ColitisColitisNCT02647866Kyowa Kirin, Inc.66